<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Source Themes Academic 4.6.3"><meta name=author content="Raphael Scheible"><meta name=description content="Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies."><link rel=alternate hreflang=en-us href=https://raphiniert.com/publication/maccari-disease-2018/><meta name=theme-color content="#d9230f"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.11.2/css/all.min.css integrity="sha256-+N4/V/SbAFiW1MPBCXnfnP9QSN3+Keu+NlB+0ev/YKQ=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/github.min.css crossorigin=anonymous title=hl-light><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/dracula.min.css crossorigin=anonymous title=hl-dark disabled><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin=anonymous><script src=https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin=anonymous async></script><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap"><link rel=stylesheet href=/css/academic.css><link rel=manifest href=/index.webmanifest><link rel=icon type=image/png href=/img/icon-32.png><link rel=apple-touch-icon type=image/png href=/img/icon-192.png><link rel=canonical href=https://raphiniert.com/publication/maccari-disease-2018/><meta property="twitter:card" content="summary"><meta property="og:site_name" content="Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"><meta property="og:url" content="https://raphiniert.com/publication/maccari-disease-2018/"><meta property="og:title" content="Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry | Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"><meta property="og:description" content="Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies."><meta property="og:image" content="https://raphiniert.com/img/raphiniert.png"><meta property="twitter:image" content="https://raphiniert.com/img/raphiniert.png"><meta property="og:locale" content="en-us"><meta property="article:published_time" content="2020-12-08T15:33:48+00:00"><meta property="article:modified_time" content="2020-12-08T16:21:50+01:00"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://raphiniert.com/publication/maccari-disease-2018/"},"headline":"Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry","datePublished":"2020-12-08T15:33:48Z","dateModified":"2020-12-08T16:21:50+01:00","author":{"@type":"Person","name":"Maria Elena Maccari"},"publisher":{"@type":"Organization","name":"Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com","logo":{"@type":"ImageObject","url":"https://raphiniert.com/img/raphiniert.png"}},"description":"Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies."}</script><script src=https://cdnjs.cloudflare.com/ajax/libs/cookieconsent2/3.1.1/cookieconsent.min.js integrity="sha256-5VhCqFam2Cn+yjw61zbBNrbHVJ6SRydPeKopYlngbiQ=" crossorigin=anonymous></script><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/cookieconsent2/3.1.1/cookieconsent.min.css integrity="sha256-zQ0LblD/Af8vOppw18+2anxsuaz3pWYyVWi+bTvTH8Q=" crossorigin=anonymous><script>window.addEventListener("load",function(){window.cookieconsent.initialise({"palette":{"popup":{"background":"#d9230f","text":"#fff"},"button":{"background":"#fff","text":"#d9230f"}},"theme":"classic","content":{"message":"This website uses cookies to ensure you get the best experience on our website.","dismiss":"Got it!","link":"Learn more","href":"/privacy/"}})});</script><meta name=google-site-verification content="5FMa7RYkPr6QEWWr1ERvyTkIv5k9JmamL7oeGWeGo9Q"><script type=text/javascript>var _paq=window._paq||[];_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);(function(){var u="//analytics.raphiniert.com/";_paq.push(['setTrackerUrl',u+'schniedel.php']);_paq.push(['setSiteId','2']);var d=document,g=d.createElement('script'),s=d.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.defer=true;g.src=u+'wutz/';s.parentNode.insertBefore(g,s);})();</script><noscript><p><img src="https://analytics.raphiniert.com/schniedel.php?idsite=2&rec=1" style=border:0 alt></p></noscript><title>Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry | Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents><aside class=search-results id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Search</h1></div><div class="col-6 col-search-close"><a class=js-search href=#><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Search... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=/><img src=/img/raphiniert.png alt="Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"></a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar aria-expanded=false aria-label="Toggle navigation">
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=/><img src=/img/raphiniert.png alt="Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"></a></div><div class="navbar-collapse main-menu-item collapse justify-content-center" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=/#about><span>Home</span></a></li><li class=nav-item><a class=nav-link href=/#projects><span>Projects</span></a></li><li class=nav-item><a class=nav-link href=/#publications><span>Publications</span></a></li><li class=nav-item><a class=nav-link href=/jesus><span>Spiritual Life</span></a></li><li class=nav-item><a class=nav-link href=/#contact><span>Contact</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class=nav-item><a class="nav-link js-search" href=#><i class="fas fa-search" aria-hidden=true></i></a></li></ul></div></nav><div class=pub><div class="article-container pt-3"><h1>Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry</h1><div class=article-metadata><div><span><a href=/authors/maria-elena-maccari/>Maria Elena Maccari</a></span>, <span><a href=/authors/hassan-abolhassani/>Hassan Abolhassani</a></span>, <span><a href=/authors/asghar-aghamohammadi/>Asghar Aghamohammadi</a></span>, <span><a href=/authors/alessandro-aiuti/>Alessandro Aiuti</a></span>, <span><a href=/authors/olga-aleinikova/>Olga Aleinikova</a></span>, <span><a href=/authors/catherine-bangs/>Catherine Bangs</a></span>, <span><a href=/authors/safa-baris/>Safa Baris</a></span>, <span><a href=/authors/federica-barzaghi/>Federica Barzaghi</a></span>, <span><a href=/authors/helen-baxendale/>Helen Baxendale</a></span>, <span><a href=/authors/matthew-buckland/>Matthew Buckland</a></span>, <span>Siobhan O. Burns</span>, <span><a href=/authors/caterina-cancrini/>Caterina Cancrini</a></span>, <span><a href=/authors/andrew-cant/>Andrew Cant</a></span>, <span>Pascal Cathébras</span>, <span><a href=/authors/marina-cavazzana/>Marina Cavazzana</a></span>, <span><a href=/authors/anita-chandra/>Anita Chandra</a></span>, <span><a href=/authors/francesca-conti/>Francesca Conti</a></span>, <span><a href=/authors/tanya-coulter/>Tanya Coulter</a></span>, <span>Lisa A. Devlin</span>, <span>J. David M. Edgar</span>, <span><a href=/authors/saul-faust/>Saul Faust</a></span>, <span><a href=/authors/alain-fischer/>Alain Fischer</a></span>, <span><a href=/authors/marina-garcia-prat/>Marina Garcia-Prat</a></span>, <span>Lennart Hammarström</span>, <span><a href=/authors/maximilian-heeg/>Maximilian Heeg</a></span>, <span><a href=/authors/stephen-jolles/>Stephen Jolles</a></span>, <span><a href=/authors/elif-karakoc-aydiner/>Elif Karakoc-Aydiner</a></span>, <span><a href=/authors/gerhard-kindle/>Gerhard Kindle</a></span>, <span><a href=/authors/ayca-kiykim/>Ayca Kiykim</a></span>, <span><a href=/authors/dinakantha-kumararatne/>Dinakantha Kumararatne</a></span>, <span><a href=/authors/bodo-grimbacher/>Bodo Grimbacher</a></span>, <span><a href=/authors/hilary-longhurst/>Hilary Longhurst</a></span>, <span><a href=/authors/nizar-mahlaoui/>Nizar Mahlaoui</a></span>, <span><a href=/authors/tomas-milota/>Tomas Milota</a></span>, <span><a href=/authors/fernando-moreira/>Fernando Moreira</a></span>, <span><a href=/authors/despina-moshous/>Despina Moshous</a></span>, <span><a href=/authors/anna-mukhina/>Anna Mukhina</a></span>, <span><a href=/authors/olaf-neth/>Olaf Neth</a></span>, <span><a href=/authors/benedicte-neven/>Benedicte Neven</a></span>, <span><a href=/authors/alexandra-nieters/>Alexandra Nieters</a></span>, <span><a href=/authors/peter-olbrich/>Peter Olbrich</a></span>, <span><a href=/authors/ahmet-ozen/>Ahmet Ozen</a></span>, <span><a href=/authors/jana-pachlopnik-schmid/>Jana Pachlopnik Schmid</a></span>, <span><a href=/authors/capucine-picard/>Capucine Picard</a></span>, <span><a href=/authors/seraina-prader/>Seraina Prader</a></span>, <span><a href=/authors/william-rae/>William Rae</a></span>, <span><a href=/authors/janine-reichenbach/>Janine Reichenbach</a></span>, <span><a href=/authors/stephan-rusch/>Stephan Rusch</a></span>, <span><a href=/authors/sinisa-savic/>Sinisa Savic</a></span>, <span><a href=/authors/alessia-scarselli/>Alessia Scarselli</a></span>, <span><a href=/authors/raphael-scheible/>Raphael Scheible</a></span>, <span><a href=/authors/anna-sediva/>Anna Sediva</a></span>, <span>Svetlana O. Sharapova</span>, <span><a href=/authors/anna-shcherbina/>Anna Shcherbina</a></span>, <span><a href=/authors/mary-slatter/>Mary Slatter</a></span>, <span><a href=/authors/pere-soler-palacin/>Pere Soler-Palacin</a></span>, <span><a href=/authors/aurelie-stanislas/>Aurelie Stanislas</a></span>, <span><a href=/authors/felipe-suarez/>Felipe Suarez</a></span>, <span><a href=/authors/francesca-tucci/>Francesca Tucci</a></span>, <span><a href=/authors/annette-uhlmann/>Annette Uhlmann</a></span>, <span><a href=/authors/joris-van-montfrans/>Joris van Montfrans</a></span>, <span><a href=/authors/klaus-warnatz/>Klaus Warnatz</a></span>, <span><a href=/authors/anthony-peter-williams/>Anthony Peter Williams</a></span>, <span><a href=/authors/phil-wood/>Phil Wood</a></span>, <span><a href=/authors/sven-kracker/>Sven Kracker</a></span>, <span><a href=/authors/alison-mary-condliffe/>Alison Mary Condliffe</a></span>, <span><a href=/authors/stephan-ehl/>Stephan Ehl</a></span></div><span class=article-date>January 2018</span></div><div class="btn-links mb-3"><a class="btn btn-outline-primary my-1 mr-1" href=https://www.frontiersin.org/articles/10.3389/fimmu.2018.00543/full target=_blank rel=noopener>PDF</a>
<button type=button class="btn btn-outline-primary my-1 mr-1 js-cite-modal" data-filename=/publication/maccari-disease-2018/cite.bib>
Cite</button>
<a class="btn btn-outline-primary my-1 mr-1" href=https://doi.org/10.3389/fimmu.2018.00543 target=_blank rel=noopener>DOI</a></div></div><div class=article-container><h3>Abstract</h3><p class=pub-abstract>Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Type</div><div class="col-12 col-md-9"><a href=/publication/#2>Journal article</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publication</div><div class="col-12 col-md-9"><em>Frontiers in Immunology</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style></div><div class=article-tags><a class="badge badge-light" href>"activated phosphoinositide 3-kinase δ syndrome"</a>
<a class="badge badge-light" href=/tags/natural-history/>"natural history"</a>
<a class="badge badge-light" href=/tags/pik3cd/>"PIK3CD"</a>
<a class="badge badge-light" href=/tags/pik3r1/>"PIK3R1"</a>
<a class="badge badge-light" href=/tags/rapamycin/>"rapamycin"</a>
<a class="badge badge-light" href=/tags/registry/>"registry"</a></div><div class=share-box aria-hidden=true><ul class=share><li><a href="https://twitter.com/intent/tweet?url=https://raphiniert.com/publication/maccari-disease-2018/&text=Disease%20Evolution%20and%20Response%20to%20Rapamycin%20in%20Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome:%20The%20European%20Society%20for%20Immunodeficiencies-Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome%20Registry" target=_blank rel=noopener class=share-btn-twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https://raphiniert.com/publication/maccari-disease-2018/&t=Disease%20Evolution%20and%20Response%20to%20Rapamycin%20in%20Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome:%20The%20European%20Society%20for%20Immunodeficiencies-Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome%20Registry" target=_blank rel=noopener class=share-btn-facebook><i class="fab fa-facebook"></i></a></li><li><a href="mailto:?subject=Disease%20Evolution%20and%20Response%20to%20Rapamycin%20in%20Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome:%20The%20European%20Society%20for%20Immunodeficiencies-Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome%20Registry&body=https://raphiniert.com/publication/maccari-disease-2018/" target=_blank rel=noopener class=share-btn-email><i class="fas fa-envelope"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https://raphiniert.com/publication/maccari-disease-2018/&title=Disease%20Evolution%20and%20Response%20to%20Rapamycin%20in%20Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome:%20The%20European%20Society%20for%20Immunodeficiencies-Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome%20Registry" target=_blank rel=noopener class=share-btn-linkedin><i class="fab fa-linkedin-in"></i></a></li><li><a href="https://web.whatsapp.com/send?text=Disease%20Evolution%20and%20Response%20to%20Rapamycin%20in%20Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome:%20The%20European%20Society%20for%20Immunodeficiencies-Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome%20Registry%20https://raphiniert.com/publication/maccari-disease-2018/" target=_blank rel=noopener class=share-btn-whatsapp><i class="fab fa-whatsapp"></i></a></li><li><a href="https://service.weibo.com/share/share.php?url=https://raphiniert.com/publication/maccari-disease-2018/&title=Disease%20Evolution%20and%20Response%20to%20Rapamycin%20in%20Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome:%20The%20European%20Society%20for%20Immunodeficiencies-Activated%20Phosphoinositide%203-Kinase%20%ce%b4%20Syndrome%20Registry" target=_blank rel=noopener class=share-btn-weibo><i class="fab fa-weibo"></i></a></li></ul></div><div class="media author-card content-widget-hr"><div class=media-body><h5 class=card-title><a href=/authors/maria-elena-maccari/></a></h5><ul class=network-icon aria-hidden=true></ul></div></div></div></div><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/highlight.min.js integrity="sha256-1zu+3BnLYV9LdiY85uXMzii3bdrkelyp37e0ZyTAQh0=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/languages/r.min.js></script><script src=https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin=anonymous></script><script>const code_highlighting=true;</script><script>const search_config={"indexURI":"/index.json","minLength":1,"threshold":0.3};const i18n={"no_results":"No results found","placeholder":"Search...","results":"results found"};const content_type={'post':"Posts",'project':"Projects",'publication':"Publications",'talk':"Talks"};</script><script id=search-hit-fuse-template type=text/x-template>
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script><script src=https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin=anonymous></script><script src=/js/academic.min.600a2e440c16093e23e26e90951c4d4b.js></script><div class=container><footer class=site-footer><p class=powered-by><a href=/privacy/>Datenschutzerklärung</a>
&#183;
<a href=/terms/>Impressum</a></p><p class=powered-by>© 2020 Raphael Scheible
<span class=float-right aria-hidden=true><a href=# class=back-to-top><span class=button_icon><i class="fas fa-chevron-up fa-2x"></i></span></a></span></p></footer></div><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Cite</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code class="tex hljs"></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i>Copy</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i>Download</a><div id=modal-error></div></div></div></div></div></body></html>